Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025.

As of late October 2025, the U.S. stock market is experiencing mixed results, with Federal Reserve Chair Jerome Powell indicating uncertainty about a potential rate cut in December. In such a climate, ...

Check the CBSE Class 11 Biotechnology Deleted Syllabus 2025–26 to know the removed topics from key units and practicals.

Debt Management: Castle Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.08, the company relies less on debt financing, maintaining a healthier balance between debt ...

CARDIO inCode-Score Genetic Risk Influences Cholesterol Risk and Prediction of Coronary Heart Disease ...

Helmholtz Munich, and the Leibniz-Institute of Plant Genetics and Crop Plant Research (IPK) have decoded the pan-genome of 33 oat lines—mapping their full genetic diversity. This comprehensive ...

The STAR-UBB Institute of the Babeş-Bolyai University (UBB) in Cluj-Napoca continues the "Studium Generale” lecture series ...

AI Overview: “As of 2025, no nation with an established universal ... was a guy named Lysenko who didn’t believe in the ...

Oat is an important crop with many health benefits and diverse applications. An international research consortium involving the Technical University ...

The pan-genome consists of the genomes of 26 modern cultivars and landraces as well as seven wild oat lines.• The team also built a ...

CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, ...

CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance maladie du ...